Gefurulimab Shows Early and Sustained Efficacy in gMG Patients
Cambridge, UK, 30 October 2025 – Alexion, AstraZeneca Rare Disease, today announced positive results from the global Phase III...
AstraZeneca
Advertisement
FDA Approves TEZSPIRE for Chronic Rhinosinusitis with Nasal Polyps
THOUSAND OAKS, Calif., October 17, 2025 — In a landmark regulatory decision, the U.S. Food and Drug Administration (FDA)...
AstraZeneca Unveils Landmark Cancer Trial Results at ESMO 2025
Madrid, Spain – October 11, 2025 – AstraZeneca presented groundbreaking clinical trial results from four major Phase III studies...
Baxdrostat Achieves Primary Endpoint in Phase III Trial for rHTN
SLondon, UK – October 7, 2025 – AstraZeneca announced that Baxdrostat met the primary endpoint in the Bax24 Phase...
Advertisement
